Get the Stockscreener App
0.7706
0.64%
-0.0094
Kala Bio Inc stock is traded at $0.7706, with a volume of 138.25K.
It is down -0.64% in the last 24 hours and down -49.68% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.78
Open:
$0.8
24h Volume:
138.25K
Relative Volume:
0.13
Market Cap:
$5.45M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.0618
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
-3.82%
1M Performance:
-49.68%
6M Performance:
-79.33%
1Y Performance:
-88.91%
1-Day Range:
$0.775
$0.81
1-Week Range:
$0.74
$0.833
52-Week Range:
$0.74
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.7763 | 5.48M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
Will KALA BIO Inc. stock outperform international peersEarnings Beat & Free Community Consensus Stock Picks - newser.com
Measuring KALA BIO Inc.’s beta against major indicesGold Moves & Weekly Top Gainers Alerts - newser.com
Real time scanner hits for KALA BIO Inc. explained2025 Breakouts & Breakdowns & Reliable Volume Spike Trade Alerts - newser.com
Applying big data sentiment scoring on KALA BIO Inc.July 2025 Closing Moves & Short-Term Trading Alerts - newser.com
Will KALA BIO Inc. outperform the marketWeekly Market Report & Expert Curated Trade Setup Alerts - newser.com
How supply chain issues affect KALA BIO Inc. stockTrade Entry Summary & Community Verified Watchlist Alerts - newser.com
What to do if you’re stuck in KALA BIO Inc.Earnings Summary Report & Community Driven Trade Alerts - newser.com
Risk vs reward if holding onto KALA BIO Inc.M&A Rumor & High Win Rate Trade Tips - newser.com
Will KALA BIO Inc. stock sustain high P E ratiosMarket Performance Recap & Consistent Profit Alerts - newser.com
Is KALA BIO Inc. stock trading at a premium valuationMarket Growth Report & Weekly High Potential Stock Alerts - newser.com
Will KALA BIO Inc. stock recover after recent dropJuly 2025 Outlook & Free Technical Pattern Based Buy Signals - newser.com
How hedge fund analytics apply to KALA BIO Inc. stockEarnings Overview Summary & Low Volatility Stock Suggestions - newser.com
Applying Elliott Wave Theory to KALA BIO Inc.Market Growth Review & Low Drawdown Investment Ideas - newser.com
Is KALA BIO Inc. stock a contrarian buyJuly 2025 Pullbacks & AI Forecasted Entry and Exit Points - newser.com
Real time alert setup for KALA BIO Inc. performanceJuly 2025 Outlook & Low Risk High Win Rate Picks - newser.com
When is the best time to exit KALA BIO Inc.2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
What drives KALA BIO Inc stock priceUtilities Sector Analysis & Rapid Portfolio Expansion - earlytimes.in
Is KALA BIO Inc a good long term investmentCash Flow Trends & Identify Breakout Stocks - earlytimes.in
Chart based exit strategy for KALA BIO Inc.July 2025 Snapshot & Safe Capital Investment Plans - newser.com
KALA BIO Inc. stock trend outlook and recovery pathJuly 2025 Short Interest & AI Enhanced Execution Alerts - newser.com
Will KALA BIO Inc. stock deliver shareholder value2025 Technical Patterns & Reliable Price Action Trade Plans - newser.com
A Heavy Trading Day Sends Biotech And Finance Stocks Reeling - Finimize
Will KALA BIO Inc. stock outperform value stocks2025 Geopolitical Influence & Verified Momentum Stock Watchlist - newser.com
Using fundamentals and technicals on KALA BIO Inc.Weekly Market Outlook & Low Risk High Win Rate Stock Picks - newser.com
Volatility clustering patterns for KALA BIO Inc.M&A Rumor & AI Optimized Trade Strategies - newser.com
Detecting support and resistance levels for KALA BIO Inc.Earnings Trend Report & High Conviction Investment Ideas - newser.com
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Oct 22 '25 |
Sale |
0.83 |
20,806 |
17,269 |
41,760 |
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):